...the time, Theravance’s GI portfolio included two serotonin (5-HT) receptor agonists, velusetrag and TAK-954 (formerly TD-8954...
...and EU regulators to discuss next steps. The compound is partnered with Alfa Wassermann S.p.A. TAK-954...

...Theravance granted Takeda worldwide rights to develop and commercialize candidate TD-8954 , a serotonin (5-HT4) receptor...
...development, sales and launch milestones, plus double-digit royalties. Theravance said a single dose of IV TD-8954...
...treat critically ill patients with enteral feeding intolerance, for which there are no FDA-approved therapies. TD-8954...

...Pharmaceutical Co. Ltd. (Tokyo:4502) a global license to develop and commercialize serotonin (5-HT4) receptor agonist TD-8954...
...in milestones through TD-8954's launch, plus double-digit royalties. Theravance said a single IV dose of TD-8954...
...treat critically ill patients with enteral feeding intolerance, for which there are no FDA-approved therapies. TD-8954...

...FDA granted Fast Track designation to TD-8954 for short-term use with enteral feeding to achieve early...
...motility disorders, including enteral feeding intolerance. Theravance Biopharma Inc. (NASDAQ:TBPH), South San Francisco, Calif. Product: TD-8954...

...agonists are in active clinical development in the U.S. for GI indications. Velusetrag (TD-5108) and TD-8954...
...ARYx Therapeutics Inc. (Pink:ARYX), Fremont, Calif. Theravance Inc. (NASDAQ:THRX), South San Francisco, Calif. Products: Naronapride; TD-8954...

...in active clinical development in the U.S. for GI indications. Velusetrag ( TD-5108 ) and TD-8954...

...in active clinical development in the U.S. for GI indications. Velusetrag ( TD-5108 ) and TD-8954...